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Background: Non-coding small RNA molecules play pivotal roles in cellular and developmental processes by
regulating gene expression at the post-transcriptional level. In human diseases, the roles of the non-coding small
RNAs in specific degradation or translational suppression of the targeted mRNAs suggest a potential therapeutic
approach of post-transcriptional gene silencing that targets the underlying disease etiology. The involvement of
non-coding small RNAs in the pathogenesis of neurodegenerative diseases such as Alzheimer’s , Parkinson’s disease
and Multiple Sclerosis has been demonstrated. Multiple sclerosis (MS) is an autoimmune disease of the central
nervous system, characterized by chronic inflammation, demyelination and scarring as well as a broad spectrum of
signs and symptoms. The current standard treatment for SM is interferon ß (IFNß) that is less than ideal due to side
effects. In this study we administered the standard IFN-ß treatment to Relapsing-Remitting MS patients, all
responder to the therapy; then examined their sncRNA expression profiles in order to identify the ncRNAs that were
associated with MS patients’ response to IFNß.
Methods: 40 IFNß treated Relapsing-Remitting MS patients were enrolled. We analyzed the composition of the
entire small transcriptome by a small RNA cloning method, using peripheral blood from Relapsing-Remitting MS
patients at baseline and 3 and 6 months after the start of IFNß therapy. Real-time qPCR from the same patients
group and from 20 additional patients was performed to profile miRNAs expression.
Results: Beside the altered expression of several miRNAs, our analyses revealed the differential expression of small
nucleolar RNAs and misc-RNAs.For the first time, we found that the expression level of miR-26a-5p changed related
to INF-β response. MiR-26a-5p expression was significantly higher in IFN-β treated RRMS patients at 3 months
treatment, keeping quite stable at 6 months treatments.
Conclusions: Our results might provide insights into the mechanisms of action of IFN-β treatment in MS and
provide fundamentals for the development of new biomarkers and/or therapeutic tools.
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Autoimmune diseases as Multiple Sclerosis (MS) are char-
acterized by complex genetic traits and patho-mechanisms
that translate into clinical heterogeneity [1,2]. Small non-
coding RNAs (sncRNAs) are essential post-transcriptional
gene regulation elements that are critical to immune system
and neurodegenerative diseases [3-5] by affecting mRNA
stability and the expression of multiple genes. Therefore, it
is becoming increasingly evident that sncRNA species, as
microRNAs, are associated with the development and pro-
gression of MS disease [6,7].
The current standard treatment for SM is interferon ß
(IFNß) that is less than ideal due to side effects. To improve
the efficacy of treatments for MS, it is desirable to find
biomarkers that allow early identification of treatment
responders and foresee responder status. Thus, better un-
derstanding of miRNA and sncRNAs role in MS develop-
ment and treatment, might contribute to the accumulation
of data to understand MS pathogenesis as well as potential
approaches for new therapeutic managing.
To shed light into the mechanisms of action of IFN-β
treatment in MS, and provide fundamentals for the devel-
opment of new biomarkers and/or therapeutic tools, we
aimed to identify non-coding small RNAs expressed by
IFN-β responder treated MS patients. Therefore, we gener-
ated small RNA complementary DNA (srcDNA) libraries
and sequenced 3000 srcDNA clones. We identified 6 ma-
ture miRNAs, 44 C/D box, 2 H/ACA box snorRNAs, 5
antisense fragment and 5 misc-RNAs classes from the per-
ipheral blood mononuclear cell (PBMC) from Relapsing-
Remitting MS patients at the baseline and after 3 and
6 months IFN-β treatment. Following, by Real-Time qPCR
assay, we assessed, that, among the identified microRNAs,
hsa-mir-26a-5p expression was significantly higher in IFN-
β treated RRMS patients at 3 months treatment, keeping
quite stable at 6 months treatments. We found, for the first
time, that the expression of a specific miRNA, hsa-mir-26a-
5p, changed during INF-β treatment in responder RRMS
patients. Functional annotations of hsa-mir-26a-5p targets
revealed that several genes were implicated in Glutamate
Receptor Signaling pathway, which is notoriously altered in
neurodegenerative diseases as MS.
Methods
Ethics statement
We obtained ethics approval for our study from the ethics
committee (also known as an Institutional Review Board)
at our institution. All the participants had the capacity to
consent and we obtained written informed consent from
all participants involved in the study.
Patients with relapsing-remitting MS and RNA isolation
We enrolled 20 patients with a diagnosis of MS accord-
ing to McDonald criteria [8], all responders to INF-βStandard clinical criteria of response to interferon beta
therapy were applied. Patients were considered responders
if there was no increase in the EDSS score and no relapses
during the follow-up period [9-11]. Additional 10 MS
non-responder patients, which were characterized by fail-
ure to respond optimally from initiation of therapy as
assessed by clinical measures, were recruited too.
Patients (naïve to the therapy) were either treated with
interferon-β and blood samples were obtained at a fixed
time during the day just before treatment and 3 and
6 months after start of the therapy. Peripheral blood was
obtained by venipuncture and immediately processed for
isolation of PBMCs. PBMCs were isolated from EDTA
blood via ficoll density gradient centrifugation. 1x107 cells
were resuspended in QiazolH (Qiagen, Hilden, Germany)
and stored at −80°C. Total RNA was extracted using the
TRIzol reagent (Invitrogen Carlsbad, CA). RNA samples
were quality-checked by identification of 18S rRNA and
28S rRNA peaks via the Agilent 2100 Bioanalyzer platform
(Agilent Technologies).
Small RNA libraries preparation and sequencing
Construction of three small RNA libraries was carried out
as previously described [12]. Total RNA (30 μg) was
pooled in 3 pools, each comprising RNA from peripheral
blood leukocytes of 20 MS patients, at baseline and 3 and
6 months after the start of interferon-β treatment. RNA
pools were size fractionated on 15% Tris/Borate/EDTA
urea polyacrylamide electrophoresis gel, and the small
ncRNA fraction in the size range of 18 to 80 nt was ex-
tracted, purified and cloned. Roughly 1000 cloned sncRNA
molecules were independently sequenced for each library.
Colony PCR was performed using 5′ and 3′ primers, and
the clones with PCR products about 110 bp in length were
sequenced.
Biological software analysis
The sequence annotation was based on information from
GenBank (http://www.ncbi.nih.gov/Genbank/index.html),
a dataset of human tRNA sequences (http://lowelab.ucsc.
edu/GtRNAdb/Hsapi/), a dataset of human sn/snoRNA
sequences (Small RNA Database, 37 snoRNA-LBME-db at
http://www-snorna.biotoul.fr/index.php, NONCODE v138
and the data base from http://research.imb.uq.edu.au/
rnadb/), a database of miRNAs (http://microrna.sanger.ac.
uk/sequences/index.shtml; release version 7.1).
Target gene prediction of miRNAs
Target genes for each miRNA were predicted using inter-
section between at least three of the eleven established tar-
get prediction programs compiled by mIRecords, such as
TargetScan (http://targetscan.org), PicTar (http://pictar.
mdc-berlin.de), miRDB (http://mirdb.org/miRDB/) [13].
To determine genes which were similarly identified by two









Total 40 17-41+/-3 2-6+/-2 1-4.7+/-2
Male 18 18.3-42+/- 2 2-5+/-2 1-4.5+/-2
Female 22 19-39+/-3 1.8-6+/-3 1-5.0 +/-3
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Filter” program from IPA (https://analysis.ingenuity.com)
was used.
Real-time qPCR for miRNA quantification
Quantitative real-time RT-PCR was performed using
RNA extracted from peripheral blood leukocytes of 20
INFβ-treated MS patients already used for cloning and
from 20 additional INFβ-treated MS patients at baseline,
3 and 6 months after the starting of the treatment. Be-
side, Real-time qPCR for miRNA quantification was also
performed using RNA extracted from peripheral blood
leukocytes of the 10 INFβ-treated MS non-responder pa-
tients at baseline, 3 and 6 months after the starting of
the treatment. To quantify miRNA expression levels,
microRNA assay-based quantitative RT-PCR (qRT-PCR)
was performed for the mature miRNAs, using miScript
II RT Kit and miScript SYBR Green PCR kit (Quiagen).
Real-time PCR was performed using a 7500 Fast Real-
Time PCR system (Applied Biosystems, Foster City, CA,
USA. RNU6B was utilized for an endogenous reference toFigure 1 Sequencing analysis of differentially expressed small sncRNA
peripheral blood of Relapsing-Remitting MS patients under IFN-β therapy, a
Number of sncRNA species per sample pool.standardize miRNA expression levels.All samples were an-
alyzed in triplicates. All the data were calibrated by the
universal reference data. miRNAs expression values were
calculated according to the 2-ΔΔCT method. Statistical sig-
nificant differences were tested by one way analysis of
variance (ANOVA), and, when the F value was significant,
by Student-Newman-Keul’ s test. P value less than 0.05 (*)
was considered statistically significant.
Real-time qPCR for mRNA quantification
To confirm the expression patterns of target genes, we
performed a quantitative RT-PCR using the comparative
Ct method. Quantitative real-time RT-PCR was performed
using RNA extracted from the 20 INFβ-treated MS pa-
tients already analyzed for cloning and from 20 additional
INFβ-treated MS patients at baseline, 3 and 6 months
after the starting of the treatment.
Transcript levels of the target genes were normalized to
β-actin (the internal control) after correcting for differ-
ences in amplification efficiencies. RT-PCR reactions (n =
3) were performed for each gene of interest using a quan-
titative real-time Light-Cycler (Roche). All genes investi-
gated have previously been identified and sequences were
available in GenBank. Primers for qRT-PCR analysis were
designed using the Primer3 program (http://www.bioinfor-
matic.nl/cgi-bin/primer3plus/primer3plus.cgi).
The final PCR reactions contained: 0.4 μM of each pri-
mer; 0.25 × SYBR Green (Invitrogen); 4 mM MgCl2 and
as template 5 μl of cDNA reverse transcribed from as. Sequencing analysis of differentially expressed small sncRNAs in the
t starting, at 3 and 6 months treatment (Library 1, 2, 3 respectively) (a)
Table 2 Small non-coding RNA classes identified by cloning
SNORD C/D SNORD H/ACA Antisense RNA miRNAs misc-RNA
C/D box 30 H/ACA box 16A C17orf76 antisense RNA 1 transcript variant 5 miR-26a-5p LOC100130249
C/D box 49A H/ACA box 16B C17orf76 antisense RNA 1 transcript variant 6 miR-3676 LOC100653240
C/D box 80 C17orf76 antisense RNA 1 transcript variant 7 miR-326 LOC100652939
C/D box 77 C17orf76 antisense RNA 1 transcript variant 13 miR-155 LOC100506834
C/D box 100 C1orf213 transcript variant 1 non-coding RNA miR-18b LOC100506679
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performed using Hotstart Taq polymerase (Qiagen) in a
final volume of 20 μl. All quantitative reactions were sub-
jected to: 95°C for 15 min followed by 45 cycles at 94°C
for 15 s, 59°C 15 s and 72°C 15 s. Melting curve analysis
was applied to all reactions to ensure homogeneity of the
reaction product. In addition, the amplicon size was
checked electrophoretically for each primer set and subse-
quent sequencing revealed that it corresponded to the
human DLG4, HOMER1, GRIN3A, SLC1A1, SLC38A1
transcripts respectively, thus verifying the identity of the
genes. Potential contamination was assessed by including
non-reverse transcribed total RNA (genomic DNA con-
tamination) and controls without template, observing no
products in these reactions.
Results
Small non coding RNAs distribution in libraries from
various IFN-β treatment stages
With the aim of characterizing the sncRNA signature
from the peripheral blood of Relapsing-Remitting MS pa-
tients under IFN-β therapy, a set of 20 cases (Table 1),
were evaluated by sncRNA cloning at starting, at 3 and
6 months treatment (IFN-0, IFN-3, IFN-6 libraries re-
spectively). About 1000 cloned sncRNA molecules were
independently sequenced for each library. This approach
allowed us to obtain a profile of sncRNAs expressed in
these cell types at different treatment stages (Figure 1).
Identified loci were further classified as known miRNA,
snoRNA, small ribosomal RNA, tRNA, antisense fragment
ncRNAs. We were able to isolate 6 mature miRNA spe-
cies deriving from known human stem-loop sequences
(Table 2). SnoRNAs were the most abundant ncRNAFigure 2 MiR-26a-5p expression levels in INF-β treated MS patient leu
from 40 IFN-β treated responder RRMS patients and from 10 IFN-β treated non-
microRNA assay-based quantitative RT-PCR following the 2-ΔΔCT method. RNU6B
expression levels. The results were expressed as relative expression levels after cspecies detected, comprising approximately 61% of the total
RNA pool (Figure 1, Table 2). A search with the mapped se-
quences from the sample libraries against known snoRNAs
identified 44 unique snoRNA loci encoding C/D-box and
2 H/ACA box snoRNAs (Table 2). The diversity of detected
snoRNA species was increased in the IFN-0 library, H/
ACA box snoRNAs were detected in IFN-3 and IFN-6 li-
braries (Figure 1). Moreover, five different unique antisense
RNA fragments and miscRNA classes, respectively were
isolated from these libraries.
miRNAs identified in different stages of IFN-β treatment
The overall expression of miRNA species was relatively in-
creased after 3 months therapy as demonstrated by the no-
ticeably higher total sequence count of miRNAs in IFN-3
and IFN-6 compared to INF-0 library. We were able to
identify 6 mature miRNA species, miR-326, miR-155, miR-
3676, miR-18b, miR-599 and miR-26a-5p deriving from
known human stem-loop sequences (miRBase 12.0).
The expression of miR-26a-5p is increased in the blood of
IFN-β treated SM patients
To validate the results obtained by cloning and to acquire a
more quantitative profile of the expression, the six miRNAs
expression was measured in 20 patients already analyzed by
cloning and in 20 additional patients by qRT-PCR, during
baseline and 3 and 6 months IFN-β. treatment.Among
these, only hsa-miR-26a-5p, which has been shown to be
mainly expressed in neural tissue [14], showed the most
significant expression change in IFN-β treated RRMS pa-
tients, at different therapy stages.MiR-26a-5p expression
was significantly higher in IFN-β treated responder RRMS
patients at 3 months treatment compared to the baseline,kocytes. The expression of mir-26a-5p was studied in the peripheral blood
responder patients, at starting, at 3 and 6 months IFN-β treatment by
was utilized for an endogenous reference to standardize microRNA
alibration with the universal reference data. P < 0.05.
Figure 3 Gene networks regulated by miR-26a-5p. Predicted miR-26a-5p target genes identified by TargetScan, PicTar , Miranda and miRBase
Target database search.
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MiR-26a-5p expression did not show any significant ex-
pression change in a group of IFN-β treated non-responder
MS patient (Figure 2).
Computational predictions of the putative targets of
miR-26a-5p
The overlap between putative targets of miRNAs and the
expression of mRNAs provides information on the bio-
logical functions and networks of genes regulated by spe-
cific miRNAs. Therefore, we explored putative miR-26a-5p
target genes by searching them on three distinct web-
accessible miRNA target databases, including TargetScan,
PicTar, and miRDB [13]. Ingenuity Pathway Analysis (IPA)
software identified biological pathways associated with pre-
dicted miR-26a-5p targets. When we looked for the most
significant associations of target genes with different cat-
egories of biological functions, we found genes shared
among the three databases, mainly involved in Nervous
System (54%), Immune Response (13%), Epigenetics (20%),
Hemopoiesis and Angiogenesis (13%) (Figure 3). Interest-
ingly, a subset of mir-26a-5p potential genes target, selected
by “MicroRNA Target Filter” program from IPA, were im-
plicated in Glutamate Receptor Signaling metabolism
(Table 3), which is altered in brains of multiple sclerosis pa-
tients [15]. Indeed, , the following hypothetical candidate
genes of miR26a-5p have been identified as target genes,
DLG4, HOMER1, GRIN3A SLC1A1, SLC38A1 (Table 3).Table 3 Predicted miR-26a-5p target genes, involved in glutam
MiRDB and PicTar target database search and selected by “Mic
Gene ID Gene symbol Gene name
NM_001128827 DLG4 discs, large homo log 4 (Drosophila)
NM_004272 HOMER1 homer homolog 1 (Drosophila)
NM_133445 GRIN3A glutamate receptor, ionotropic, N-meth
NM_004170 SLC1A1 solute carrier family 1 (neuronal/epithel
glutama te transporter, system Xag), me
NM_001077484 SLC38A1 solute carrier family 38, member(DLG4), a key player in neuronal and glutamate signaling
[16] HOMER1 (homer homolog 1) and GRIN3A (glutam-
ate receptor ionotropic N-methyl-d-aspartate 3A), are all
related to glutamate signaling [17].
Differential expression of miR-26a-5p gene targets in the
blood of IFN-β treated SM patients
The expression of miR-26a-5p gene targets, representing
key role in Glutamate Receptor Signaling biological path-
way selected by “MicroRNA Target Filter” program from
IPA (Table 3), was evaluated by qPCR. Among the subset
of five gene target, DLG4 showed a significant expression
change in blood samples from IFN-β treated RRMS pa-
tients, at different treatment stages. We were able to detect
2.5 fold decreases in DLG4 expression in the blood from
3 months IFN-β treated SM patients, keeping quite
stable at 6 months (Figure 4). As shown in Figure 5, after
6 months IFN-β treatment, DLG4 expression showed a
significant negative correlation to miR-26a-5p expression
(Pearson’s correlation r = − 0.995 (P = 0.003). Since DLG4
contains a 8-nt miR-26a-5p binding site in its 3′ UTR,
these results might suggest that miR-26a-5p up-regulation
could have a significant impact on the regulation of DLG4
gene expression in INF- β treated responder subjects.
Discussion
At present, consistent data regarding alterations in the ex-
pression of miRNAs in MS are reported [18-20]; however,ate receptor signaling pathway, identified by TargetScan,
roRNA Target Filter” program from IPA








Figure 4 DLG4 expression levels in INF-β treated MS patient leukocytes. Significant up-regulation of the expression of putative miR-26a-5p
targets, DLG4, was evaluated by qPCR in INF-b treated MS patients leukocytes. P < 0.05.
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other small sncRNA in this disease are lacking. Moreover,
little is known about small regulatory RNAs and how they
contribute to pathogenesis, progression and transcriptome
changes in MS and to the mechanisms of action of IFN-β
treatment in MS patients. This information can be utilized
as a novel biomarker to predict identification of INF-β re-
sponders during the therapy as well to be applied to de-
velop novel therapy for MS patients.
Here, we detected a pronounced increase in the three li-
braries for several snoRNAs, providing further support for
high metabolic activity and elevated protein-synthesis rate.
Interestingly, in addition to their function in ribosomal
maturation, snoRNA species or their derivates have beenFigure 5 Correlation of miR-26a-5p and DLG4 expression level in MS
The expression level of miR-226a-5p and DLG4 was determined by quantit
and DLG4 expression levels was observed (Pearson’s correlation coefficientimplicated in processes associated to alternative splicing
events [21] and genomic imprinting [22]. Recent findings
have demonstrated that snoRNAs can also function as miR-
NAs [23]. The HBII-52 C/D box snoRNA associated with
Prader-Willi syndrome is one important example [24].
Additional research is needed to investigate whether this
unconventional function of snoRNAs is a large spread
mechanism of gene regulation and whether this keeps true
for snoRNAs identified in this research.
Five different antisense RNA fragment and 5 miscRNA
classes were isolated in these libraries. Lately it has been
shown that antisense RNA transcripts are associated not
only to imprinting and X inactivaction, but can occur at
non-imprinted autosomal loci. This mechanism can have apatients leukocytes after 6 months IFN-β treatment.
ative Real Time RT-PCR. A significant correlation between miR-26a-5p
= −0.995, P = 0.003).
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tions as well as in inherited disorders [25]. Our screening
revealed that blood miRNA expression can be associated
with patient’s INF-β response. Not all MS patients re-
spond to interferon beta therapy, and to date, there is a
lack of markers that can correlate with responsiveness
to interferon-β therapy in MS. In a previous study, the
expression of five selected miRNAs in a group of glatira-
mer acetate and interferon-beta treated MS patients, from
peripheral blood mononuclear cell, has been evaluated to
detect a potential impact of immuno-modulatory ther-
apy on deregulated miRNAs [26]: however, miRNAs ex-
pression did not differ between treatment-naıve and
IFN-beta treated RRMS patients. In our research, mir-
26a-5p, showed a significant change in the level of ex-
pression, based on the INF-βresponse, at the different
stages of treatment in INF-β treated responder RRMS
(Figure 2). Studies have demonstrated that glutamater-
gic regulation can take place in MS symptoms and treat-
ment [27]. Under pathological conditions an excess of
glutamate in the synaptic space can trigger a toxic cas-
cade leading to cell death. This neuro-excitotoxicity
cascade might have a key role linking the presence of in-
flammation to axonal injury in multiple sclerosis [28].
Interferon-β (IFN)-β reduces symptoms of the relaps-
ing–remitting form of MS. Beside the effects on immuno-
modulatory system and metalloproteinase 9 [29], IFN-β
has been shown to be neuroprotective against the toxicity
induced by activated microglia in cortical neurons and
microglia co-cultures, suppressing the production of glu-
tamate and superoxide by activated microglia [30] Consid-
ering that the expression level mir-26a-5p changed, these
variations can have a significant impact on a patient’s
INF − β-response and glutamate activity. The expression
levels of miR-26a-5p in the response to treatment were
consistently and significantly higher in IFN-β treated
RRMS patients at 3 months treatment, keeping stable at
6 months treatments in all patients. Beside, qPCR results
have demonstrated that DLG4 expression decreased
after 3 months treatment, showing a significant inverse
correlation to mir-26a-5p expression. The DLG4 tran-
script of 4.2 kb is most abundant in brain, but also
expressed in leukocytes [16]. These results are interest-
ing, especially if we consider that post-synaptic density
protein 95 (DLG4), a key player in neuronal signaling,
has been identified as a putative regulators connecting 64%
of the identified proteins in rats induced acute experimen-
tal autoimmune encephalomyelitis (EAE), a well character-
ized disease model of MS [31]. We hypothesized, therefore,
that mir-26a-5p might down-regulate the expression level
of glutamate-signaling related genes in INFβ- treated MS
patients. However, the underlying molecular mechanism
warrants further research also in neuronal cells and/or ani-
mal model.Conclusions
In conclusion, our research revealed that a blood miRNA
expression can be associated with a patient’s INF response.
Since information on miRNA is regularly being updated,
we are planning in the future to perform more analysis
using a larger number and different kind of sample as
neuronal tissue. As result, miRNA profiling can be useful
as a biological marker for predicting the identification of
INF-β responders during the therapy, thereby reducing in-
effective treatments. Beside, miRNA expression profile can
facilitate the accumulation of data to develop novel thera-
peutic targets for MS [32].
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